Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Pharmacogenetics and Pharmacogenomics: Overview01:29

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Gene-Specific Outcomes After Central Nervous System Metastases in Germline BRCA1- and BRCA2-Associated Breast Cancer.

Cancers·2026
Same author

Hereditary Transthyretin Amyloidosis in Austria: Clinical, Genetic, and Demographic Insights from a Nationwide Cohort.

Journal of clinical medicine·2026
Same author

Changes in cardiac parameters during venetoclax treatment.

Haematologica·2025
Same author

Performance of LDL-C only compared to the Dutch Lipid Clinic Network Score for screening of familial hypercholesterolaemia: the Austrian experience and literature review.

European journal of preventive cardiology·2024
Same author

New-Onset Complement-Mediated Thrombotic Microangiopathy during the COVID-19 Pandemic.

Kidney & blood pressure research·2024
Same author

Prospective Trial on the Pharmacokinetics of Clopidogrel in Hemodialysis Patients.

Kidney international reports·2024
Same journal

Assessing neonatal and paediatric acute kidney injury: current practices and insights from the IFCC C-ETPLM International Laboratory Survey.

Clinical chemistry and laboratory medicine·2026
Same journal

A novel comprehensive non-invasive prenatal testing system for the simultaneous detection of single-gene disorders, chromosomal structural rearrangements, and aneuploidy.

Clinical chemistry and laboratory medicine·2026
Same journal

Fish-shaped erythrocytes and pincer cells co-occur in distinct hematological disorders and are associated with anemia severity.

Clinical chemistry and laboratory medicine·2026
Same journal

Artificial general intelligence and the clinical laboratory: a paradigm shift toward Lab 2.0.

Clinical chemistry and laboratory medicine·2026
Same journal

Addressing property and unit discordance in laboratory interoperability: the role of NPU as a governance layer.

Clinical chemistry and laboratory medicine·2026
Same journal

Ethical evaluation of reflex and reflective testing in conformity with ISO 15189:2022 at the value-based laboratory medicine era.

Clinical chemistry and laboratory medicine·2026
See all related articles

Related Experiment Video

Updated: Jun 6, 2026

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

Pharmacogenetics guided anticoagulation.

Raute Sunder-Plassmann1, Christine Mannhalter

  • 1Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria.

Clinical Chemistry and Laboratory Medicine
|November 11, 2010
PubMed
Summary
This summary is machine-generated.

Genetic variations impact common diseases, but pharmacogenetic knowledge for anticoagulation is underutilized. Testing genetic variants can prevent adverse drug reactions and improve treatment outcomes.

More Related Videos

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

Related Experiment Videos

Last Updated: Jun 6, 2026

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

Area of Science:

  • Human genetics
  • Pharmacogenetics
  • Genomics

Background:

  • Genetic advances enable rare disease prevention and tailored cancer therapies.
  • Genetic variations' role in common disease risk and outcomes remains unclear.
  • Genome-wide association studies are beginning to address these questions.

Purpose of the Study:

  • To review the impact of genetic alterations on anticoagulation therapy.
  • To highlight the underutilization of pharmacogenetic knowledge in clinical practice.

Main Methods:

  • Review of current literature on human genetics and pharmacogenetics.
  • Focus on genetic variants in vitamin K epoxide reductase and cytochrome P450 enzymes.
  • Analysis of their impact on anticoagulation strategies.

Main Results:

  • Pharmacogenetic knowledge, especially for anticoagulation, is not widely applied.
  • Genetic variants in vitamin K epoxide reductase and cytochrome P450 affect drug response.
  • Pre-treatment genetic testing can prevent adverse drug reactions and treatment failure.

Conclusions:

  • Genetic testing prior to anticoagulation therapy can optimize treatment.
  • Translating pharmacogenetic findings into clinical practice is crucial for patient safety and efficacy.
  • Further research is needed to fully understand genetic influences on common diseases.